blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3300734

EP3300734 - USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF AUTOIMMUNE DISORDERS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.07.2020
Database last updated on 04.11.2024
FormerThe patent has been granted
Status updated on  12.07.2019
FormerGrant of patent is intended
Status updated on  01.04.2019
FormerRequest for examination was made
Status updated on  02.11.2018
FormerThe application has been published
Status updated on  02.03.2018
Most recent event   Tooltip15.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 17.08.2022  [2022/33]
Applicant(s)For all designated states
Inflammatory Response Research, Inc.
515 E. Micheltorena, Suite G
Santa Barbara, CA 93103 / US
[2018/14]
Inventor(s)01 / MAY, Bruce, Chandler
5333 Hollister Ave 208
Santa Barbara, CA 93111 / US
 [2019/18]
Former [2018/14]01 / MAY, Bruce, Chandler
5333 Hollister Ave 208
Santa Barbara, CA California 93111 / US
Representative(s)Zacco Sweden AB
P.O. Box 5581
Löjtnantsgatan 21
114 85 Stockholm / SE
[N/P]
Former [2018/14]Zacco Sweden AB
P.O. Box 5581
114 85 Stockholm / SE
Application number, filing date17195345.807.03.2014
[2018/14]
Priority number, dateUS201361780420P13.03.2013         Original published format: US 201361780420 P
[2018/14]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP3300734
Date:04.04.2018
Language:EN
[2018/14]
Type: A3 Search report 
No.:EP3300734
Date:18.04.2018
Language:EN
[2018/16]
Type: B1 Patent specification 
No.:EP3300734
Date:14.08.2019
Language:EN
[2019/33]
Search report(s)(Supplementary) European search report - dispatched on:EP19.03.2018
ClassificationIPC:A61P37/00, A61K31/47, A61K31/495, A61K31/573, A61K31/136, A61K31/454, A61K31/496
[2018/16]
CPC:
A61K31/495 (EP,US); A61K31/135 (EP,US); A61K31/136 (EP,US);
A61K31/454 (EP,US); A61K31/47 (EP,US); A61K31/496 (EP,US);
A61K31/4985 (EP,US); A61K31/519 (EP,US); A61K31/573 (EP,US);
A61K38/193 (EP,US); A61P37/00 (EP); A61P37/02 (EP);
A61P37/06 (EP); A61P43/00 (EP) (-)
C-Set:
A61K31/136, A61K2300/00 (EP,US);
A61K31/454, A61K2300/00 (EP,US);
A61K31/47, A61K2300/00 (US,EP);
A61K31/495, A61K2300/00 (US,EP);
A61K31/496, A61K2300/00 (EP,US);
A61K31/519, A61K2300/00 (US,EP);
A61K31/573, A61K2300/00 (US,EP)
(-)
Former IPC [2018/14]A61K31/496, A61K31/47, A61K31/136, A61K31/454, A61K31/495, A61K31/4985, A61K31/519, A61K31/573, A61K38/19, A61K31/135
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/49]
Former [2018/14]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:VERWENDUNG VON LEVOCETIRIZIN UND MONTELUKAST ZUR BEHANDLUNG VON AUTOIMMUNERKRANKUNGEN[2018/14]
English:USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF AUTOIMMUNE DISORDERS[2018/14]
French:UTILISATION DE LÉVOCÉTIRIZINE ET DE MONTÉLUKAST DANS LE TRAITEMENT DES MALADIES AUTO-IMMUNES[2018/14]
Examination procedure18.10.2018Examination requested  [2018/49]
18.10.2018Date on which the examining division has become responsible
02.04.2019Communication of intention to grant the patent
28.06.2019Fee for grant paid
28.06.2019Fee for publishing/printing paid
28.06.2019Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP14778050.6  / EP2969010
Opposition(s)03.06.2020No opposition filed within time limit [2020/33]
Fees paidRenewal fee
06.10.2017Renewal fee patent year 03
06.10.2017Renewal fee patent year 04
13.03.2018Renewal fee patent year 05
13.03.2019Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU07.03.2014
AL14.08.2019
AT14.08.2019
CY14.08.2019
CZ14.08.2019
DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
MC14.08.2019
MK14.08.2019
MT14.08.2019
NL14.08.2019
PL14.08.2019
RO14.08.2019
RS14.08.2019
SI14.08.2019
SK14.08.2019
SM14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
GR15.11.2019
IS14.12.2019
PT16.12.2019
IE07.03.2020
LU07.03.2020
BE31.03.2020
CH31.03.2020
LI31.03.2020
[2022/33]
Former [2022/28]HU07.03.2014
AL14.08.2019
AT14.08.2019
CY14.08.2019
CZ14.08.2019
DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
MC14.08.2019
MT14.08.2019
NL14.08.2019
PL14.08.2019
RO14.08.2019
RS14.08.2019
SI14.08.2019
SK14.08.2019
SM14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
GR15.11.2019
IS14.12.2019
PT16.12.2019
IE07.03.2020
LU07.03.2020
BE31.03.2020
CH31.03.2020
LI31.03.2020
Former [2021/13]AL14.08.2019
AT14.08.2019
CZ14.08.2019
DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
MC14.08.2019
NL14.08.2019
PL14.08.2019
RO14.08.2019
RS14.08.2019
SI14.08.2019
SK14.08.2019
SM14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
GR15.11.2019
IS14.12.2019
PT16.12.2019
IE07.03.2020
LU07.03.2020
BE31.03.2020
CH31.03.2020
LI31.03.2020
Former [2021/08]AL14.08.2019
AT14.08.2019
CZ14.08.2019
DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
MC14.08.2019
NL14.08.2019
PL14.08.2019
RO14.08.2019
RS14.08.2019
SI14.08.2019
SK14.08.2019
SM14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
GR15.11.2019
IS14.12.2019
PT16.12.2019
IE07.03.2020
LU07.03.2020
CH31.03.2020
LI31.03.2020
Former [2021/04]AL14.08.2019
AT14.08.2019
CZ14.08.2019
DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
MC14.08.2019
NL14.08.2019
PL14.08.2019
RO14.08.2019
RS14.08.2019
SI14.08.2019
SK14.08.2019
SM14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
GR15.11.2019
IS14.12.2019
PT16.12.2019
LU07.03.2020
Former [2020/50]AL14.08.2019
AT14.08.2019
CZ14.08.2019
DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
MC14.08.2019
NL14.08.2019
PL14.08.2019
RO14.08.2019
RS14.08.2019
SI14.08.2019
SK14.08.2019
SM14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
GR15.11.2019
IS14.12.2019
PT16.12.2019
Former [2020/37]AL14.08.2019
AT14.08.2019
CZ14.08.2019
DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
NL14.08.2019
PL14.08.2019
RO14.08.2019
RS14.08.2019
SI14.08.2019
SK14.08.2019
SM14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
GR15.11.2019
IS14.12.2019
PT16.12.2019
Former [2020/36]AL14.08.2019
AT14.08.2019
CZ14.08.2019
DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
NL14.08.2019
PL14.08.2019
RO14.08.2019
RS14.08.2019
SK14.08.2019
SM14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
GR15.11.2019
IS14.12.2019
PT16.12.2019
Former [2020/27]AL14.08.2019
AT14.08.2019
CZ14.08.2019
DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
NL14.08.2019
PL14.08.2019
RO14.08.2019
RS14.08.2019
SK14.08.2019
SM14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
GR15.11.2019
PT16.12.2019
IS24.02.2020
Former [2020/25]AL14.08.2019
AT14.08.2019
CZ14.08.2019
DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
NL14.08.2019
PL14.08.2019
RO14.08.2019
RS14.08.2019
SK14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
GR15.11.2019
PT16.12.2019
IS24.02.2020
Former [2020/24]AL14.08.2019
AT14.08.2019
DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
NL14.08.2019
PL14.08.2019
RO14.08.2019
RS14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
GR15.11.2019
PT16.12.2019
IS24.02.2020
Former [2020/23]AL14.08.2019
AT14.08.2019
DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
NL14.08.2019
PL14.08.2019
RO14.08.2019
RS14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
GR15.11.2019
IS14.12.2019
PT16.12.2019
Former [2020/22]AL14.08.2019
DK14.08.2019
EE14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
NL14.08.2019
RS14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
GR15.11.2019
IS14.12.2019
PT16.12.2019
Former [2020/17]AL14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
NL14.08.2019
RS14.08.2019
TR14.08.2019
BG14.11.2019
NO14.11.2019
GR15.11.2019
IS14.12.2019
PT16.12.2019
Former [2020/15]AL14.08.2019
FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
NL14.08.2019
RS14.08.2019
BG14.11.2019
NO14.11.2019
GR15.11.2019
IS14.12.2019
PT16.12.2019
Former [2020/12]FI14.08.2019
HR14.08.2019
LT14.08.2019
LV14.08.2019
NL14.08.2019
RS14.08.2019
BG14.11.2019
NO14.11.2019
GR15.11.2019
IS14.12.2019
PT16.12.2019
Former [2020/10]FI14.08.2019
LT14.08.2019
NL14.08.2019
BG14.11.2019
NO14.11.2019
PT16.12.2019
Former [2020/09]FI14.08.2019
LT14.08.2019
NL14.08.2019
NO14.11.2019
Former [2020/08]LT14.08.2019
NO14.11.2019
Documents cited:Search[A]WO9509652  (KENNEDY INST OF RHEUMATOLOGY [GB], et al) [A] 1-12 * page 25, lines 28-30 * * page 27, lines 18-19 *;
 [A]WO03002109  (AB SCIENCE [FR], et al) [A] 1-12 * page 11, lines 21-23 * * page 25, lines 22-23 *;
 [A]US2007020352  (TRIPP MATTHEW [US], et al) [A] 1-12 * paragraph [0072] *;
 [A]WO2011159821  (MAY BRUCE CHANDLER [US]) [A] 1-12 * page 22, line 13 *;
 [A]US2012071509  (GORE VINAYAK GOVIND [IN], et al) [A] 1-12 * paragraphs [0051] , [0069] *;
 [A]US2013011395  (SPIES THOMAS [US], et al) [A] 1-12 * paragraph [0117] *;
 [A]US2013029949  (HOFFMANN MATTHIAS [DE], et al) [A] 1-12 * paragraphs [0006] , [0010] , [0510] *;
 [A]WO2013013490  (SHANGHAI INST MATERIA MEDICA [CN], et al) [A] 1-12* abstract *
by applicant   - KLOEPFER KM et al., "Effects of montelukast in patients with asthma after experimental inoculation with human rhinovirus 16", Annals Allergy Asthma Immunology, (20110000), vol. 106, doi:doi:10.1016/j.anai.2010.11.021, pages 252 - 257, XP028153707

DOI:   http://dx.doi.org/10.1016/j.anai.2010.11.021
    - BISGAARD, H. et al., "Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncitial virus bronchiolitis in children", Am. J. Respir. Crit. Care Med., (20080000), vol. 178, doi:doi:10.1164/rccm.200706-910OC, pages 854 - 860, XP055141819

DOI:   http://dx.doi.org/10.1164/rccm.200706-910OC
    - PROESMANS, M. et al., "Montelukast does not prevent reactive airway disease in young children hospitalized for RSV bronchiolitis", Acta Paediatr., (20090000), vol. 98, pages 1830 - 34
    - SEARS, M.R.; JOHNSTON, N.W., "Understanding the September asthma epidemic", J. Allergy Clin. Immunol., (20070000), vol. 120, doi:doi:10.1016/j.jaci.2007.05.047, pages 526 - 29, XP022212624

DOI:   http://dx.doi.org/10.1016/j.jaci.2007.05.047
    - BACHARIER, L.B. et al., "Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing", J. Allergy Clin. Immunol., (20080000), vol. 122, pages 1127 - 35
    - DILORENZO G, "Randomized placebo- controlled trial comparing desloratadine and montelukast in combined therapy for chronic idiopathic urticaria", J Allergy Clin Immunol, (20040000), vol. 114, pages 619 - 25
    - MELTZER, EO, "Rhinosinusitis: Developing guidance for clinical trials", J Allergy Clin Immunol, (20061100), page S20
    - FOKKENS W, "EAACI position paper on rhinosinusitis and nasal polyps executive summary", Allergy, (20050000), vol. 60, pages 583 - 601
    - FOKKENS, W, "European Position Paper on Rhinosinusitis and Nasal Polyps group (2007) European position paper on rhinosinusitis and nasal polyps", Rhinology, (20070000), vol. 20, pages 1 - 136
    - CASALE M, "Nasal Polyposis: From Pathogenesis to Treatment, an Update", Inflammation & Allergy - Drug Targets, (20110000), vol. 10, pages 158 - 163
    - ECCLES R., "Understanding the Symptoms of the Common Cold and Influenza", Lancet Infectious Diseases, (20050000), vol. 5, no. 11, doi:doi:10.1016/S1473-3099(05)70270-X, pages 718 - 725, XP005135624

DOI:   http://dx.doi.org/10.1016/S1473-3099(05)70270-X
    - CINES DB; BLANCHETTE VS, "Immune Thrombocytopenia Purpura", N Engl J Med, (20020000), vol. 346, doi:doi:10.1056/NEJMra010501, pages 995 - 1008, XP009049770

DOI:   http://dx.doi.org/10.1056/NEJMra010501
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.